The efficacy and role of tremelimumab

Tremelimumab (tremelimumab), as an immune checkpoint inhibitor, plays a regulatory role in the immune system by inhibiting the CTLA-4 protein. CTLA-4 is an inhibitory receptor that blocks T cell activation. By binding to CTLA-4, temsitumumab blocks the inhibitory signals of T cells in the body and the binding of to inhibitory molecules, thereby releasing the inhibition of T cell activity, promoting the activation of T cells and enhancing the immune system's ability to attack tumor cells

The function of temsitumumab is to activateT cells and enhance the immune system's ability to attack tumor cells. It helps the immune system recognize and kill tumor cells, thereby inhibiting the growth and spread of tumors. Texitumumab is widely used in the treatment of cancers such as unresectable hepatocellular carcinoma and non-small cell lung cancer. Its main target is tumor cells. By activating the immune system, it enhances the immune attack power of tumor cells and inhibits the growth and spread of tumors. In some patients, temsitumumab can induce durable treatment responses. This means that the immune system can continue to attack the tumor even if the drug is stopped.

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.